市場調査レポート
商品コード
1179874

筋骨格系疾患治療の世界市場-2023-2030

Global Musculoskeletal Diseases Treatment Market - 2023-2030

出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
筋骨格系疾患治療の世界市場-2023-2030
出版日: 2023年01月05日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

筋骨格系疾患治療の世界市場規模は、予測期間(2023~2030年)にCAGR4.8%で成長すると予測されています。

筋肉、骨、関節、およびその近傍の結合組織の機能障害は、一時的または永久的な機能制限や関与をもたらし、筋骨格系障害として知られる150以上の異なる疾患や状態を構成しています。主な筋骨格系疾患は、長期的な痛みや障害を引き起こすことが多いため、他の一般的な病状よりも治療費が高くなります。

市場力学

世界の筋骨格系疾患治療市場を牽引する主な要因は、この市場が主に筋骨格系疾患の数の増加、筋骨格系疾患の治療における技術開発、および筋骨格系疾患の割合に対する国民の意識の 高まりによって推進されているためです。

市場は主に筋骨格系疾患の増加によって牽引されており、市場の成長を牽引することが期待されています。

世界保健機関は、2022年に世界で17億1000万人が筋骨格系疾患に罹患すると推定しています。腰痛は160の異なる国で障害の唯一の原因となっており、筋骨格系疾患は世界的に障害の主な原因となっています。筋骨格系疾患は、動作や器用さを著しく制限するため、労働力の早期退職、幸福度の低下、社会参加能力の低下を招きます。筋骨格系疾患とそれに関連する機能制限を持つ人々の数は、人口の増加と高齢化により常に増加しています。

対関節炎2021によると、英国では2000万人以上(人口の約3分の1)が、関節炎や腰痛などの筋骨格系(MSK)疾患を患っています。関節炎などのMSK疾患の患者さんは通常、疲労、こわばり、動作や手先の不自由さに加え、これらの疾患の主な症状の一つである痛みに悩まされています。そのため、新興国の主要企業は、筋骨格系疾患治療を採用することで市場をリードする大きな優位性を持っています。

治療費の高さが市場拡大を鈍化させる可能性があります。

高価な研究開発費と複雑な行政手続きによって、市場は阻害されると予想されます。さらに、病院の主な懸念は、筋骨格系疾患の治療による副作用の可能性が、市場を停止させることです。

COVID-19の影響分析

世界的に、COVID-19の大流行はヘルスケアシステムに有害な影響を及ぼしました。多くの業界プレイヤーの活動や業績がパンデミックによって影響を受け、活動が徐々に低下しています。さらに、2020年前半、筋骨格系疾患の治療市場はCOVID-19の大流行によって大きな影響を受けた。パンデミックの初期段階では、ロックダウンの急速な実施により流通網に支障をきたしました。さらに、世界中がウイルス対策に集中する中、運動器系疾患の治療が中断または遅延しました。COVID-19の典型的な症状は、リウマチや筋骨格系疾患の症状に似ているため、これらの症状を適切かつ最適に治療することが困難です。

さらに、COVID-19感染症の治療に用いられる様々な抗ウイルス剤の副作用が、事態をさらに複雑にしています。しかし、監禁事件後、市場は徐々に回復し、運動器疾患の治療薬の需要が高まり、サプライチェーンが強化されました。また、製薬会社は、患者さんがより効果的な治療法を選択できるよう、先進的な疾患治療薬の開発を進めています。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 市場は主に運動器疾患の増加別牽引されています。
      • 筋骨格系疾患の治療における技術的発展
    • 抑制要因
      • 治療費の高騰が市場拡大の妨げになる可能性
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • プライシング分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 疾患タイプ別

  • 関節炎
  • 変形性関節症
  • 骨粗鬆症
  • 脊椎炎
  • 外傷性骨折
  • サルコペニア
  • 線維筋痛症
  • その他

第8章 イメージングモダリティ別

  • 磁気共鳴画像(MRI)
  • コンピュータ断層撮影(CT)
  • 超音波診断装置
  • その他

第9章 薬物別

  • アセトアミノフェン
  • 非ステロイド性抗炎症薬(NSAIDs)
  • 抗神経障害性疼痛治療薬
  • その他

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第13章 企業プロファイル

  • Pfizer
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Koninklijke Philips
  • Siemens
  • Canon Medical Systems
  • Hitachi
  • Shimadzu
  • Fujifilm
  • Toshiba
  • Accuray
  • MR Solutions
  • Globus Medical Inc

第14章 筋骨格系疾患治療の世界市場-DataM

目次
Product Code: DMPH6109

Market Overview

The global musculoskeletal diseases treatment market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 4.8% during the forecast period (2023-2030).

Muscle, bone, joint, and nearby connective tissue dysfunction resulting in temporary or permanent restrictions in functioning and involvement make up over 150 different diseases and conditions known as musculoskeletal impairments. Major musculoskeletal diseases are more expensive to treat than other common medical conditions because they frequently cause long-term pain and disability.

Market Dynamics

The major factors driving the global musculoskeletal diseases treatment market are due to the market is primarily being driven by a rise in the number of musculoskeletal diseases, technological developments in the treatment of musculoskeletal diseases and increasing public awareness of the rate of musculoskeletal diseases.

The market is primarily being driven by a rise in the number of musculoskeletal diseases is expected to drive the market's growth.

World Health Organization estimates that 1.71 billion people worldwide will suffer from musculoskeletal diseases in 2022. Low back pain is the sole cause of disability in 160 different nations, and musculoskeletal diseases are the main cause of disability globally. Musculoskeletal disorders severely restrict movement and dexterity, which results in early retirement from the workforce, decreased levels of well-being, and a decreased capacity to engage in society. The number of people with musculoskeletal diseases and related functional restrictions is constantly rising due to population expansion and aging.

Over 20 million people in the UK (approximately a third of the population), according to versus arthiritis 2021, suffer from musculoskeletal (MSK) conditions like arthritis and low back pain. Patients with MSK diseases like arthritis usually suffer pain, which is one of the main symptoms of these conditions, in addition to fatigue, stiffness, and a loss of movement and dexterity. As a result, key players in developing nations have significant advantages in leading the market by adopting musculoskeletal illness treatment.

The high cost of treatment could slow market expansion.

The market is anticipated to be hampered by expensive R&D expenses and a complicated government process. Additionally, the hospitals' main fear is that the potential for side effects from the treatment of musculoskeletal diseases would halt the market.

COVID-19 Impact Analysis

Globally, the COVID-19 pandemic had a detrimental effect on healthcare systems. Many industry players' activities and financial results have been impacted by the Pandemic and the gradually declining of activities. Additionally, in the first half of 2020, the market for the treatment of musculoskeletal diseases was significantly impacted by the COVID-19 epidemic. During the Pandemic's early stages, the distribution network was hampered by the rapid implementation of lockdown. Furthermore, while the globe concentrated on the virus-fighting effort, treatments for musculoskeletal diseases were suspended or delayed. The typical COVID-19 manifestations, which can mimic the symptoms of rheumatic and musculoskeletal diseases, make it difficult to treat these conditions appropriately and optimally.

Additionally, the side effects of the various antiviral medications used to treat COVID-19 infection further complicate matters. However, the market gradually recovered following the lockdown, which increased the demand for medications for musculoskeletal disorders and strengthened the supply chain. In addition, pharmaceutical companies are developing advanced disease medications to encourage patients to choose more effective therapies.

Segment Analysis

The arthritis segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Arthritis is the most prevalent disease type in the musculoskeletal disease treatment market. Inflammation of one or more joints, such as the knees, knuckles, wrists, or ankles, is known as arthritis or joint disease. Joint pain, edema, and stiffness can develop as arthritis progresses from its first stage of joint inflammation. The CDC estimates that approximately 58.5 million Americans, or one out of four US adults (23.7%), have arthritis that a doctor has officially diagnosed.

Women are more likely to have arthritis (23.5%) than men (18.1%), it is more prevalent in adults with fair or poor health (40.5%) than in adults with excellent or very good health (15.4%), and it is less prevalent in adults who meet physical activity guidelines (18.1%) than in adults who are insufficiently active or inactive (23.1% and 23.6%, respectively). Age is a factor in the prevalence of arthritis. Drugs frequently treat arthritis because they can lessen inflammation and persistent pain. Anti-inflammatory drugs sold over the counter and painkillers may reduce arthritic discomfort. Corticosteroids can lower inflammation and suppress the immune system.

Geographical Analysis

North America holds the largest market share in the global musculoskeletal diseases treatment market.

North America dominates the global musculoskeletal diseases treatment market has a major influence on adopting various medical procedures. The treatment of musculoskeletal diseases market is growing in North America due to the rising prevalence of inflammatory bowel diseases and the availability of more hospitals and improved diagnostics facilities. The United States Bone and Joint Initiative (USBJI) predicts that by 2040, 1 in 5 U.S Americans will be 65 or older, roughly equaling the proportion of people in that age group.

Nearly two-thirds of people with arthritis are under 65, even though one in two adults aged 65 and older already has some arthritis. 67 million persons are expected to have arthritis by the year 2030. Both inflammatory types of osteoarthritis and inflammatory forms of arthritis are more common in women. Additionally, over the next few years, it is anticipated that the critical healthcare benefits provided by employer-sponsored health insurance plans and the growing investments by vendors in cutting-edge and affordable medications will boost this regional market.

Competitive Landscape

The musculoskeletal diseases treatment market is moderately competitive with local and global companies' presence Pfizer, Koninklijke Philips, Siemens, Canon Medical Systems, Hitachi, Shimadzu, Fujifilm, Toshiba, Accuray, MR Solutions, Globus Medical and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth.

Globus Medical Inc.

Overview: A manufacturer of medical devices, Globus Medical Inc. (Globus) creates and markets healthcare products for persons with musculoskeletal diseases. The business provides surgical instruments, biologics, accessories, and implanted devices for various spinal, orthopedic, and neurosurgery treatments. Ankle fracture system, clavicle fracture system, distal radius fracture system, proximal tibia fracture system, and small fragment fracture system are some of its main offerings. Additionally, it provides clever computer-assisted systems intended to enhance surgeons' capabilities and simplify surgical procedures.

Product Portfolio:

ANTHEM Ankle Fracture System: Three types of distal fibula plates are available with contours to match patient anatomy and minimize the need for intraoperative bending. Low profile plates are designed for minimal screw prominence to help reduce soft tissue irritation. Clamps designed specifically for ankle anatomy facilitate fracture reduction. Radiolucent Weitlaners and retractors aid in fracture site visibility.

The global musculoskeletal diseases treatment market report would provide access to approx.: 45 + market data table, 40 + figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The market is primarily being driven by a rise in the number of musculoskeletal diseases
      • 4.1.1.2. Technological developments in the treatment of musculoskeletal diseases
    • 4.1.2. Restraints:
      • 4.1.2.1. The high cost of treatment could slow market expansion
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. Arthritis
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Osteoarthritis
  • 7.4. Osteoporosis
  • 7.5. Spondylitis
  • 7.6. Traumatic fractures
  • 7.7. Sarcopenia
  • 7.8. fibromyalgia
  • 7.9. Others

8. By Imaging Modality

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 8.1.2. Market Attractiveness Index, By Imaging Modality
  • 8.2. Magnetic Resonance Imaging (MRI)
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Computed Tomography (CT)
  • 8.4. Ultrasound
  • 8.5. Others

9. By Medication

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 9.1.2. Market Attractiveness Index, By Medication
  • 9.2. Acetaminophen
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • 9.4. Anti-neuropathic pain medications
  • 9.5. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacy
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacy
  • 10.4. Online Pharmacy

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Pfizer
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Koninklijke Philips
  • 13.3. Siemens
  • 13.4. Canon Medical Systems
  • 13.5. Hitachi
  • 13.6. Shimadzu
  • 13.7. Fujifilm
  • 13.8. Toshiba
  • 13.9. Accuray
  • 13.10. MR Solutions
  • 13.11. Globus Medical Inc

LIST NOT EXHAUSTIVE

14. Global Musculoskeletal diseases treatment Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Application
  • 14.3. Contact Us